VolitionRx's New Blood Test Detects Feline Cancer with 100% Specificity

VolitionRx (NYSE American: VNRX), a multinational epigenetics company, has announced groundbreaking results from a clinical study of its Nu.Q Vet Feline assay, demonstrating high accuracy in detecting lymphoma—the most common cancer in cats. The blood-based test achieved 100% specificity, meaning no false positives, while detecting over 80% of feline lymphomas, positioning it as what the company expects to be the world's first simple and affordable liquid biopsy test for feline cancer. This development addresses a critical gap in veterinary medicine, as feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed. Veterinarians have long sought such a screening solution, and VolitionRx's success follows the international rollout of its canine cancer test, demonstrating the versatility of its technology across species.

The company plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution networks, including reference laboratories and point-of-care platforms. VolitionRx, which operates research and development centers in Belgium with offices in the U.S. and London, is dedicated to advancing the science of epigenetics to save lives and improve outcomes for both people and animals through earlier detection and monitoring of life-altering diseases. Their broader mission includes developing cost-effective blood tests for various cancers and diseases associated with NETosis, such as sepsis, aiming to prolong patient lives and enhance quality of life. For more details, the full press release is available at https://ibn.fm/SI9RB, and additional information can be found on the company's website at https://volition.com/.

This news was distributed via BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, focusing on biotechnology, biomedical sciences, and life sciences. BMW provides comprehensive corporate communications solutions, including access to wire services, article syndication to over 5,000 outlets, press release enhancement, and social media distribution through IBN's network. By leveraging these resources, BMW helps companies like VolitionRx reach a wide audience of investors, influencers, consumers, and journalists, cutting through information overload to deliver impactful news. For more on BMW's services, visit https://www.BioMedWire.com, and explore the broader IBN network for additional insights into market trends and innovations.